HK Stock MarketDetailed Quotes

CANSINOBIO (06185)

Watchlist
  • 24.740
  • +1.740+7.57%
15min DelayMarket Closed Aug 7 16:07 CST
6.11BMarket Cap-4948.00P/E (TTM)

About CANSINOBIO Company

Founded in China in 2009, the company is committed to delivering solutions for the prevention and treatment of infectious diseases worldwide. It focuses on the research, development, manufacturing, and commercialization of innovative, high-quality, and affordable human vaccines, positioning itself as a leading high-tech biopharmaceutical enterprise. The company's mission has always been "to provide innovative, high‑quality, and accessible vaccines globally," with the corporate vision of "unending innovation, a world free from disease." Today, the company is primarily engaged in the R&D, production, and commercialization of cutting‑edge vaccines. Its key products include meningococcal conjugate vaccines, pneumococcal conjugate vaccines, acellular pertussis–diphtheria–tetanus vaccines, and recombinant poliovirus vaccines, among others. Corporate honors include: National High‑Tech Enterprise; Key Laboratory of Recombinant and Conjugate Vaccines Against Respiratory Bacterial Pathogens of Tianjin Municipality; Collaborative Talent‑Training Base of Nankai University; Model Collective of Tianjin Municipality; as well as numerous accolades such as Tianjin Manufacturing Single‑Item Champion Enterprise, Tianjin Specialized, Fine, Distinctive, and Innovative SME, Advanced‑Level Smart Factory of Tianjin, and First Prize for Scientific and Technological Progress of Tianjin.

Company Profile

Symbol06185
Company NameCANSINOBIO
ISINCNE100003F01
Listing DateMar 28, 2019
Issue Price22.00
Shares Offered57.25M share(s)
FoundedJan 13, 2009
Registered AddressChina
ChairmanXuefeng YU
Secretaryjinzhaomingjing cui
Audit InstitutionDeloitte Touche Tohmatsu Certified Public Accountants, Deloitte Huayong Certified Public Accountants (Special General Partnership)
Company CategoryOther
Registered OfficeRoom 401–420, 4th Floor, West Zone Biopharmaceutical Park, No. 185 Nan大街, West Zone, Tianjin Economic-Technological Development Area
Head Office and Principal Place of Business

Room 1901, 19th Floor, Phase I, Lee Garden, 33 Hysan Road, Causeway Bay, Hong Kong

Fiscal Year Ends12-31
Employees1134
MarketHong Kong motherboard
Phone022-58213766
Fax022-58213626
Emailir@cansinotech.com
Websitehttp://www.cansinotech.com.cn
Business

Permitted Items: Operation of Class III medical devices; pharmaceutical manufacturing; import and export of pharmaceuticals; retail sale of pharmaceuticals; wholesale of pharmaceuticals; import and export of goods; import and export of technology. (For projects that, pursuant to law, require approval, business activities may be conducted only upon approval by the relevant authorities; the specific scope of operations shall be subject to the approval documents or licenses issued by the competent authorities.) General Items: Sale of Class I medical devices; sale of Class II medical devices; medical research and experimental development; technical services, technological development, technical consulting, technical exchange, technology transfer, and technology promotion. (Except for projects that, pursuant to law, require approval, business activities may be carried out independently in accordance with the law on the strength of the business license.)

Company Executives

  • Name
  • Position
  • Salary
  • Xuefeng YU
  • Chairman of the Board, Chief Executive Officer, Executive Director, General Manager, Nomination Committee Member, Members of the Remuneration and Performance Review Committee, Authorized Representative
  • 4.31M
  • Shou Bai CHAO
  • Executive Director, Deputy General Manager, Chief Operating Officer
  • 2.77M
  • jing wang
  • Executive Director, Deputy General Manager, Chief Commercial Officer
  • 3.74M
  • zhicheng li
  • Non-executive Director, Members of the Remuneration Committee, Audit Committee Member
  • 300.00K
  • yaoliang zhang
  • Independent Non-Executive Director, Chair of the Audit Committee, Members of the Remuneration and Performance Review Committee
  • --
  • min zuo
  • Independent Non-Executive Director, Chair of the Remuneration Committee, Nomination Committee Member
  • 27.00K
  • xuefeng ji
  • Independent Non-Executive Director, Chair of the Nominating Committee, Audit Committee Member, Members of the Remuneration Committee
  • 27.00K
  • tao zhu
  • Chief Scientific Officer
  • --
  • Dongxu QIU
  • Executive Vice President, Senior Vice President
  • --
  • jin cui
  • Joint Company Secretary, Board Secretary
  • --
  • mingjing zhao
  • Joint Company Secretary, Authorized Representative
  • --
Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.39%
Sample Name
Sample Code
 +6.60%
Sample Name
Sample Code
 +5.78%
4
PETROCHINA
00857
+5.26%
5
KUNLUN ENERGY
00135
+3.47%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +13.01%
Sample Name
Sample Code
 +4.69%
Sample Name
Sample Code
 +4.34%
4
Hangzhou Shunwang Technology
300113
+1.70%
5
Iflytek Co.,ltd.
002230
+1.02%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -